6 de abril de 2026

Hepatitis and Hepatotropic Viruses Overview

Introduction to Hepatitis

• The session begins with a greeting and an overview of the topics: hepatotropic and non-hepatotropic viruses, followed by autoimmune liver diseases.

• Emphasis on categorizing viral hepatitis into two groups based on their tropism for hepatocytes.

Hepatotropic vs. Non-Hepatotropic Viruses

• Hepatotropic viruses specifically target hepatocytes, with replication cycles occurring within the liver; examples include hepatitis A, B, C, D, and E.

• Non-hepatotropic viruses do not have a specific tropism for the liver; inflammation is secondary to other infections.

Key Non-Hepatotropic Viruses

Herpesviruses

• Discussion of herpesviruses (e.g., HSV types 1 & 2), which can integrate into host DNA and reactivate throughout life.

• Severity of hepatitis caused by these viruses depends on the patient's immune status; typically mild in immunocompetent individuals but severe in immunocompromised patients.

Specific Herpesviruses

• Varicella-Zoster Virus (VZV), associated with chickenpox and shingles, primarily affects immunocompromised patients when causing hepatic issues.

• Epstein-Barr Virus (EBV), known for infectious mononucleosis, has a characteristic presentation including atypical lymphocytes detectable via Paul-Bunnell test.

Diagnostic Markers for EBV Infection

• The triad of symptoms includes atypical lymphocytosis, splenomegaly, and mild hepatitis; transaminases may elevate significantly during acute infection.

• Various serological markers are discussed: IgM indicates acute infection while IgG suggests past exposure or reactivation.

Cytomegalovirus (CMV)

• CMV can cause congenital infections leading to neonatal complications; biopsy may reveal granulomatous hepatitis.

• Reactivation in immunosuppressed patients poses high morbidity/mortality risks; diagnosis confirmed through PCR testing.

Other Notable Viruses

Roseolovirus and Kaposi's Sarcoma-associated Herpesvirus

• Roseolovirus causes sudden rash illness in children but can lead to mild hepatic involvement.

• Kaposi's Sarcoma-associated herpesvirus also linked to mild hepatitis but rarely causes acute liver failure.

Dengue Fever as a Common Cause of Hepatitis

• Discussion highlights dengue fever as a prevalent cause of viral hepatitis during summer months.

Dengue and Hepatitis: Understanding the Impact on the Liver

Overview of Dengue Types

• Dengue can present as either simple dengue or dengue with warning signs, which includes symptoms like abdominal pain, persistent vomiting, ascites, bleeding, hepatomegaly, and other hematological issues.

• Severe dengue is defined by organ compromise; specifically, hepatic involvement occurs when transaminases exceed 1000.

Hepatic Effects of Dengue

• Dengue is cytopathic and damages hepatocytes. Typically, TGO (AST) levels rise more than TGP (ALT), indicating severe dengue when transaminases are above 1000.

• Various infections such as syphilis, leptospirosis, and brucellosis can also affect liver function. The liver filters all antigens from the portal vein that receives intestinal antigens.

Systemic Inflammation and Liver Response

• Any systemic disease causing inflammation may elevate transaminase levels without indicating direct liver disease; it reflects a systemic reaction to viral or bacterial infections.

Pathotropic Viruses Affecting Hepatocytes

• Pathotropic viruses specifically target hepatocytes rather than cholangiocytes. Their destruction leads to elevated TGO and TGP levels.

• Hepatitis A virus (HAV), part of the Picornaviridae family with six genotypes (only three infect humans), primarily affects individuals through genotype one.

Epidemiology of Hepatitis A

• The average age of hepatitis A infection varies globally; in countries like the USA and Australia, most immunity is seen in those over 40 due to vaccination history.

• In Peru, immunity peaks between ages 10–20 because childhood infections lead to antibody development early on.

Transmission Routes for Hepatitis A

• HAV enters the bloodstream via the gastrointestinal tract and reaches hepatocyte membranes through portal circulation. It has two infectious forms: non-enveloped and quasi-enveloped viruses that enter cells via specific receptors.

• Fecal-oral transmission is the primary route for hepatitis A infection; however, it can survive in seawater for up to four weeks.

Infection Dynamics in Adults vs. Children

• During incubation, HAV is present in liver tissue but decreases once symptoms appear. Blood transfusions from infected donors during this period pose a risk for transmission.

• Sexual transmission has been noted among men who have sex with men (MSM), often linked to fecal contamination during oral sex practices.

Symptomatic Presentation of Hepatitis A

• Adult infections typically result in symptomatic presentations such as jaundice and fever while less than 30% of children show symptoms. Recovery rates exceed 99%, with no specific treatment required for hepatitis A infection.

Hepatitis A and B Overview

Hepatitis A: Key Insights

• Hepatitis A has a recovery rate of approximately 70%, with about 30% of patients requiring a liver transplant. Rare forms include prolonged hepatitis and relapsing hepatitis, where symptoms can recur after initial recovery.

• The incubation period for hepatitis A is around 30 days, but it can extend up to 50 days. Common prodromal symptoms include fever, malaise, nausea, vomiting, and abdominal pain.

• All forms of hepatitis A are acute; none become chronic. Typical presentations include icteric (jaundiced) or anicteric forms in children, while atypical forms may involve prolonged jaundice lasting over 12 weeks.

• Diagnosis involves considering the patient's history of food consumption up to 50 days prior. Initial viral symptoms may escalate to jaundice within a week.

• For acute hepatitis diagnosis, IgM antibodies should be tested; IgG may also be present if there was a past infection. Treatment is supportive as the disease resolves spontaneously.

Prevention and Vaccination

• As of 2023, the hepatitis A vaccine is included in vaccination schedules with one dose recommended by health authorities; private patients often receive two doses spaced six months apart.

Hepatitis B: Key Insights

Virus Characteristics

• Hepatitis B virus (HBV) is an enveloped DNA virus that primarily affects mammals. It has a spherical shape measuring about 42 nanometers and consists of an inner core containing its genome and an outer lipoprotein layer housing surface antigens.

• HBV replicates through a unique cycle involving entry into hepatocytes via NTCP receptors, leading to the formation of covalently closed circular DNA (cccDNA), which integrates into host cell DNA creating stable mini-chromosomes.

Transmission Routes

• Transmission occurs mainly through sexual contact or blood exposure. Infected bodily fluids such as saliva, vaginal secretions, semen, menstrual fluid can transmit the virus; vertical transmission during childbirth is also possible but rare.

Diagnostic Challenges

• Diagnosing hepatitis B can be complex due to multiple markers present during infection stages. The surface antigen indicates early infection or chronicity while total antibodies reflect past exposure to the virus.

Hepatitis B: Understanding Antibodies and Viral Load

Overview of Antibodies in Hepatitis B

• The total antibody response will be positive, with IgM being the subclass that indicates acute infection. IgM positivity is similar to hepatitis A during an acute phase or upon viral reactivation.

• The presence of antigen E indicates a high viral load, suggesting significant virus replication and increased risk of transmission to others. Conversely, antibodies against antigen E typically correlate with low viral load.

Antibody Development and Infection Timeline

• Surface antibodies indicate protection from infection, either through vaccination or previous exposure. The incubation period for hepatitis B ranges from 1 to 6 months, which is longer than that of hepatitis A.

• Upon initial infection (month 0), surface antigen appears first due to its location on the lipoprotein layer. This is followed by increases in total antibodies and IgM as the virus replicates.

Progression and Recovery from Infection

• As the body controls the infection, surface antigens disappear while antibodies against them remain as lifelong markers. In acute infections, both surface antigens and IgM are positive alongside detectable viral load.

• Post-recovery, individuals retain total antibodies but no longer replicate the virus; they may develop anti-E antibodies if previously infected.

Vaccination vs. Natural Infection

• Individuals vaccinated without prior exposure will have negative total antibodies but positive surface antibodies due to vaccination effects.

• Chronic hepatitis B occurs when surface antigens persist for six months or more post-infection. If diagnosed with acute infection symptoms like jaundice and elevated transaminases, follow-up after six months is essential to check for chronicity.

Management of Chronic Hepatitis B

• Follow-up testing at six months determines if a patient has transitioned from acute to chronic hepatitis B based on continued presence of surface antigens.

• Children infected perinatally often experience non-jaundiced clinical courses but have a high chance (30%-90%) of developing chronic infections compared to adults (5%).

Treatment Options for Chronic Cases

• Treatment options include entecavir or tenofovir; interferon may also be used in some cases. Not all patients require treatment—criteria exist based on viral load levels.

• Acute infections are generally not treated unless there’s hepatic failure; chronic cases are selectively treated based on established guidelines rather than universally applied protocols.

Cure vs. Management Strategies

• While treatments can manage hepatitis B effectively by achieving undetectable viral loads, no cure exists due to integration into host DNA making eradication challenging.

Vaccination Protocol

• Hepatitis B vaccination follows a schedule of doses at 0, 1, and 6 months for optimal long-term immunity; antibody levels are checked post-vaccination primarily in healthcare professionals exposed to bloodborne pathogens.

Hepatitis Overview and Treatment

Hepatitis B Vaccination Protocol

• Antibodies against Hepatitis B are dosed; if levels are below 10, a booster is administered. The vaccination schedule for newborns includes doses at 2, 4, and 6 months.

• In adults, the standard vaccination schedule differs: it consists of doses at 0, 1, and 6 months.

Understanding Hepatitis C

• Hepatitis C is an RNA virus from the flavivirus family with six genotypes that infect humans. Its structure is simpler than that of Hepatitis B.

• The primary mode of transmission for Hepatitis C is through blood; in developed countries, intravenous drug use is a significant risk factor.

• Sexual transmission risk is low (less than 5% among lifelong monogamous couples). In Peru, intravenous drug use is rare; thus, transmission often occurs via blood transfusions or hemodialysis.

Chronic Nature of Hepatitis C

• Approximately 70% of those infected with Hepatitis C develop chronic infections which can lead to cirrhosis and hepatocellular carcinoma.

• Patients with chronic infection may also develop lymphomas due to the virus's lymphotropic properties.

Diagnosis and Markers for Hepatitis C

• Diagnosis involves checking for total antibodies against the virus and viral load (RNA). A positive antibody test indicates either acute or chronic infection based on clinical presentation.

• If both antibody and RNA tests are negative, there’s no infection. Notably, there’s currently no vaccine for Hepatitis C.

Advances in Treatment for Hepatitis C

• Since around 2020, treatment advancements have significantly improved cure rates to nearly 100%, using direct antiviral agents like Sofosbuvir and Velpatasvir.

• These treatments are pan-genotypic—effective across all genotypes—and typically require a course of about 12 weeks.

Hepatitis D: Coinfection Risks

Characteristics of Hepatitis D

• Hepatitis D cannot infect independently; it requires co-infection with hepatitis B. Transmission routes mirror those of hepatitis B: sexual contact, blood exposure, or vertical transmission.

Implications of Coinfection vs. Superinfection

• Coinfection (simultaneous infection with both viruses) tends to be less severe than superinfection (where someone already infected with hepatitis B becomes infected with hepatitis D), which increases risks for cirrhosis and liver cancer.

Diagnosis and Testing Recommendations

• Diagnosing hepatitis D involves testing for specific antibodies and viral RNA similar to hepatitis C protocols. There’s no vaccine available but treatment options exist.

Hepatitis E Overview

Genotypes and Transmission Routes

• There are four genotypes of hepatitis E affecting humans; genotypes 1 and 2 transmit fecal-orally while genotypes 3 and 4 are zoonotic.

Clinical Outcomes

• Most cases resolve without chronicity except in immunocompromised patients who may experience prolonged illness requiring follow-up testing after six months to check for potential chronicity.

Understanding Hepatitis and Autoimmune Liver Diseases

Key Concepts in Hepatitis Diagnosis

• The discussion begins with the importance of understanding antibodies, particularly focusing on hepatitis B antibodies, which are considered complex.

• A case study is presented where a 20-year-old patient exhibits symptoms like malaise, dark urine, and jaundice. Initial tests for hepatitis A return negative.

• The speaker suggests that acute hepatitis B is likely due to recent sexual contact; key markers such as surface antigen and IgM antibodies are discussed.

• The presence of positive E antigen indicates high replication and infectiousness in acute cases of hepatitis B.

• If a patient has only surface antigen antibodies without core antibodies, it implies vaccination rather than infection.

Understanding Antibody Responses

• If both surface antigen and core antibody are present, it indicates past infection with recovery since the body produced its own antibodies.

• The speaker emphasizes that once recovered from an infection, core antibodies remain detectable but do not indicate active disease.

• Treatment options for hepatitis B include entecavir and tenofovir; interferon is reserved for specific genotypes with high viral loads but has lower cure rates.

Interpreting Test Results

• A scenario is posed regarding a patient with elevated transaminases but negative viral load despite positive anti-hepatitis C antibodies.

• It’s clarified that without a detectable viral load, the patient does not have an active infection; this suggests a past resolved infection rather than current disease.

Introduction to Autoimmune Liver Diseases

Overview of Autoimmune Hepatitis

• Transitioning to autoimmune liver diseases, specifically autoimmune hepatitis which destroys liver cells.

• This condition predominantly affects females and shows two peaks in incidence: ages 10–30 and 40–60 years old.

Pathophysiology Insights

• The pathophysiology involves loss of tolerance to autoantigens within the liver due to various triggers including genetic factors or infections.

• The liver's role as an immunologically tolerant organ becomes compromised leading to autoimmune responses against its own tissues.

Hepatitis Autoinmune: Presentación y Diagnóstico

Introducción a la Hepatitis Autoinmune

• La hepatitis autoinmune se caracteriza por la activación de células autoinmunes contra autoantígenos, resultando en la destrucción de hepatocitos. Los síntomas iniciales son vagos, incluyendo ictericia, náuseas, vómitos y malestar general.

• Un 40% de los pacientes presentan artralgias. La hepatitis autoinmune puede manifestarse como una falla hepática aguda o como hepatitis aguda severa sin encefalopatía.

Formas de Presentación

• Puede presentarse como hepatitis crónica con transaminasas elevadas (200-2000), pero sin aumento significativo de bilirrubina. El diagnóstico puede realizarse incluso cuando el paciente ya tiene cirrosis.

• Generalmente, el inicio es insidioso; los pacientes pueden tener síntomas durante seis meses a un año antes del diagnóstico. El examen físico varía según el grado de enfermedad hepática.

Diagnóstico Clínico

• Se observa un patrón hepatocelular en las transaminasas que pueden estar más de 50 veces elevadas respecto al valor normal. Las enzimas colestásicas también pueden estar levemente elevadas.

• Aunque el 80% de los pacientes desarrollan anticuerpos específicos, estos no son exclusivos para hepatitis autoinmune y pueden aparecer en otras enfermedades autoinmunes o incluso en personas sanas.

Tipos de Hepatitis Autoinmune

• Existen dos tipos principales: Tipo 1 (más común en adultos con cirrosis y manifestaciones extrahepáticas como artritis y anemia hemolítica) y Tipo 2 (frecuente en niños con hepatitis aguda).

• Los anticuerpos típicos para tipo 1 incluyen ANA y SMA; para tipo 2 se destacan anti-LKM1.

Criterios Diagnósticos

• Se utilizan criterios diagnósticos que suman puntos basados en transaminasas altas, patrón colestásico, niveles elevados de inmunoglobulina G y presencia de anticuerpos positivos.

• Los criterios simplificados consideran cinco ítems clave para establecer un diagnóstico definitivo si se obtienen al menos siete puntos.

Biopsia Hepática

• En biopsias típicas se observa un espacio porta marcado donde las células plasmáticas atacan los hepatocitos, lo que lleva a la pérdida del contorno normal del espacio porta.

• La presencia aumentada de células plasmáticas entre hepatocitos es característica del daño hepático asociado a la hepatitis autoinmune.

Hepatitis Autoimmune and Primary Biliary Cholangitis Overview

Key Characteristics of Autoimmune Hepatitis

• The formation of rosettes in liver cells is indicative of autoimmune hepatitis, characterized by inflammatory cell infiltration known as benulitis and peri-benulitis.

• Diagnosis involves checking for elevated transaminases and specific antibodies; if results are inconclusive, a biopsy may be necessary to confirm the condition.

Treatment Approaches for Autoimmune Hepatitis

• Common associated conditions include vitiligo, diabetes, autoimmune hemolytic anemia, polyarthritis, and hypothyroidism.

• Chronic hepatitis can lead to cirrhosis; thus, treatment primarily involves corticosteroids like prednisone combined with azathioprine.

Monitoring Disease Progression

• Control of the disease is monitored through the reduction of transaminase levels; alternative immunosuppressants may be considered if there’s insufficient response to initial treatments.

Transitioning to Primary Biliary Cholangitis (PBC)

• PBC was previously termed primary biliary cirrhosis but has been renamed to avoid confusion regarding its association with cirrhosis. It specifically targets bile ducts rather than hepatocytes.

Symptoms and Diagnosis of PBC

• Symptoms include cholestasis leading to elevated alkaline phosphatase levels; it predominantly affects women over 15 years old. Pruritus occurs in about 20% of patients and correlates with disease severity.

• Diagnostic suspicion arises from direct hyperbilirubinemia alongside cholestasis; the hallmark antibody for PBC is antimitochondrial antibody (AMA), present in over 90% of cases.

Further Diagnostic Steps

• If AMA is negative but PBC is still suspected, other specific antinuclear antibodies (e.g., anti-gp210 or anti-sp100) can support diagnosis.

• Differentiating between intrahepatic and extrahepatic cholestasis requires imaging studies such as abdominal ultrasound to check for bile duct dilation.

Biopsy Findings in PBC

• In cases where non-invasive tests are inconclusive, a biopsy may reveal non-suppurative cholangitis characterized by inflammatory cell presence around bile ducts.

Associated Conditions with PBC

• Patients with PBC often have associated autoimmune diseases such as Sjögren's syndrome, systemic sclerosis, or Hashimoto's thyroiditis. Dyslipidemia can also occur due to cholesterol accumulation.

Osteoporosis and Cholestasis: Understanding the Connection

Osteoporosis in Patients with Cholestasis

• Patients with cholestasis often experience osteoporosis due to vitamin absorption deficiencies.

• In women, there is an unexplained association between cholestasis, breast cancer, and recurrent urinary infections.

• Chronic cholestasis can lead to complications such as cirrhosis or hepatocellular carcinoma.

Treatment Options for Cholestasis

• The primary treatment for cholestasis is ursodeoxycholic acid; effectiveness is evaluated after one year.

• If there is incomplete response, second-line treatments include obeticholic acid and vesafibrates.

Primary Sclerosing Cholangitis: A Rare Disease

Overview of Primary Sclerosing Cholangitis (PSC)

• PSC is a rare inflammatory cholangiopathy that predominantly affects males.

• It causes fibrosis leading to strictures in intrahepatic and extrahepatic bile ducts, typically presenting at ages 15 and 35.

Association with Other Conditions

• Up to 70% of PSC cases are associated with inflammatory bowel disease, particularly ulcerative colitis.

• Patients have a doubled risk of developing colon cancer due to ulcerative colitis.

Symptoms and Diagnosis of PSC

Clinical Presentation

• Most patients are asymptomatic; diagnosis often occurs through abnormal liver function tests indicating cholestasis.

• Common symptoms include fatigue and pruritus caused by cholestasis; physical examination may reveal jaundice or right upper quadrant pain.

Diagnostic Procedures

• Ultrasound may reveal biliary stones or strictures; further investigation via MRCP (Magnetic Resonance Cholangiopancreatography) may be warranted if ultrasound results are inconclusive.

Diagnosis Confirmation for PSC

Imaging Techniques

• Diagnosis of PSC relies on imaging findings from MRCP showing characteristic bile duct strictures.

• A rare variant exists where diagnosis requires liver biopsy rather than imaging alone.

Complications Associated with PSC

Potential Complications

• Recurrent cholangitis can occur due to poor bile drainage leading to infection; patients also face increased risks for cholecystitis and biliary carcinoma.

Treatment Limitations

• There are no pharmacological treatments that improve survival rates in PSC patients. Management focuses on treating strictures when necessary.

Overlap Syndromes in Autoimmune Diseases

Understanding Overlap Syndromes

• Autoimmune diseases like autoimmune hepatitis can coexist with primary biliary cholangitis or primary sclerosing cholangitis, termed overlap syndromes.

Implications for Treatment

• Patients may present positive markers for multiple conditions requiring combined treatment approaches based on the active diseases present.

Overlap Syndrome and Diagnostic Approaches

Understanding Overlap Syndrome

• The discussion begins with the definition of Overlap Syndrome, which involves a combination of autoimmune hepatitis and primary biliary cholangitis (PBC).

• A case study is presented involving a 35-year-old patient experiencing abdominal pain, leading to elevated alkaline phosphatase levels indicating potential liver issues.

Diagnostic Steps for Abdominal Pain

• An abdominal ultrasound is recommended to determine if cholestasis is intrahepatic or extrahepatic, revealing irregularities in bile duct viability.

• The importance of magnetic resonance cholangiography (MRCP) is highlighted as a modern diagnostic tool, replacing older methods like endoscopic retrograde cholangiopancreatography (ERCP).

Case Study: Cirrhosis Diagnosis

• Another case involves a 30-year-old patient with jaundice and fatigue; lab results indicate high alkaline phosphatase and bilirubin levels.

• The diagnosis of cirrhosis is confirmed through ultrasound findings showing nodular liver borders and portal hypertension.

Autoimmune Considerations

• Antibody testing reveals positive anti-LKM1 antibodies, suggesting an autoimmune etiology for the patient's condition.

• Discussion on treatment options includes ursodeoxycholic acid as the first-line therapy for conditions like PBC.

Monitoring Liver Conditions

• Regular screening for cirrhosis and hepatocellular carcinoma (HCC) is emphasized, recommending biannual ultrasounds for at-risk patients.

• It’s noted that HCC typically occurs in patients with cirrhosis rather than those without it.

Criteria for Overlap Diagnosis

• Patients suspected of having overlap syndrome often present with both cholestatic patterns and hepatocellular injury markers.

• Paris criteria are mentioned as guidelines to diagnose overlap syndrome effectively between autoimmune hepatitis and PBC.

Final Remarks on Evaluation Process

• The session concludes with logistical discussions about upcoming evaluations and assessments related to the topics covered.

Discussion on Formative Evaluation Scheduling

Scheduling the Evaluation

• The conversation begins with a greeting and a discussion about formative evaluation, indicating its importance in the context.

• A request is made to schedule an evaluation for the following day, emphasizing flexibility regarding timing.

• The doctor confirms that participants have approximately 4 to 5 hours allocated for completing the evaluation.

• Various time slots are proposed for the evaluation, with suggestions ranging from late afternoon to evening hours.

• The final suggestion of scheduling from 4 PM to 8 PM is deemed practical for all involved.